RNS REACH
13 July 2021
RUA Life Sciences plc
("RUA" or the "Company")
Full Year Results Investor Presentation
Results Webinar: open to all investors
RUA Life Sciences (AIM:RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM), will be conducting an Investor Presentation webinar covering their FY results for the year ended 31 March 2021.
The event will take place at 2.00pm on Friday 16th July 2021.
The online presentation is open to all existing and potential shareholders. Questions can be submitted during the presentation to be addressed at the end.
To register for the event, please go to: https://www.equitydevelopment.co.uk/news-and-events/rua-life-sciences-full-year-results-investor-presentation-16th-july-2021
A recording will be available after the event at https://www.equitydevelopment.co.uk/research/tag/rua-life-sciences
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0) 77 3071 8296
David Richmond, CEO Tel: +44 (0) 78 9999 6400
Equity Development Tel: +44 (0) 20 7065 2692
Hannah Crowe
Shore Capital (Nominated Adviser and Joint Broker)
Tom Griffiths/David Coaten Tel: +44 (0) 20 7408 4080
Cenkos Securities plc (Joint Broker) Tel: +44 (0) 20 7397 8900
Russell Cook/Max Gould (Corporate Finance)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.
Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon™, a long-term implantable polyurethane.
Whether it is licensing Elast-Eon™, manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.
Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.
The Group's four business units are:
| RUA Medical: | End-to-end contract designer and manufacturer of medical devices and implantable fabric specialist. |
| RUA Biomaterials: | Licensor of Elast-Eon™ polymers to the medical device industry. |
| RUA Vascular: | Commercialisation of large bore polymer sealed grafts and soft tissue patches. |
| RUA Structural Heart: | Development of polymeric leaflet systems for heart valves. |
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
